Facebook-f Twitter Instagram
How to Join Us
Job Openings
Research

Giorgetti Group

Hematopoietic Stem Cell Biology and Leukemogenesis

Identification of Molecular and Cellular Pathways involved in hematopoietic stem cell specification and oncogenic transformation

Hematopoiesis is a hierarchical process controlled by a rare population of multipotent hematopoietic stem cells (HSCs). Inherited disorders affecting HSCs and their progeny are responsible for malignant and non-malignant hematological diseases. The goal of studying hematopoietic development is not only to elucidate the development trajectory of blood cells, but also to provide insights for treatment of hematological disorders.
Headshot of Alessandra Giorgetti
Alessandra Giorgetti
Principal Investigator, Regenerative Medicine Program of IDIBELL
Associate Professor, Department of Pathology and Experimental Therapy, University of Barcelona
Associated Group Leader of P-CMRC
agiorgetti@idibell.cat
Biosketch

Lab Focus-Elucidating molecular and cellular mechanism regulating hematopoietic development

Hematopoietic stem cells (HSCs) are considered the base of adult hematopoiesis. Currently, most of these hematological disorders are curable by HSC transplantation. However, the limited availability of optimally human matched donor remains a challenge, especially for individuals of non-Caucasian background or mixed ethnicity. Human pluripotent stem cells (PSCs), including embryonic stem cells (hESCs) and induced PSCs (hiPSCs), can differentiate in vitro into various hematopoietic cell type and could represent an ideal source of customized HSCs for clinical application. Furthermore, HSCs derived from patient-iPSCs not only represent an invaluable hematological disease modeling but might provide a cell-based platform for therapeutic screening. The production of engrafting HSCs from human PSCs will depend on the accurate recapitulation of embryonic hematopoiesis. Currently, our laboratory is working on 1) identification of developmental pathways involved in the generation of HSCs to direct the differentiation of PSCs into clinically relevant hematopoietic cells; 2) developing iPS cell based models of blood cancer stem cell development. These goals will be realized by combining genomics, transcriptomics, gene editing and cell biological techniques.

Why it matters

Understanding the hematopoietic development it is crucial to faithfully reproduce the process of HSC development in vitro generating cell replacement therapies for the treatment of blood-related genetic diseases and leukaemia.

Giorgetti’s Lab Twitter account

Keywords

Hematopoietic Stem Cell (HSC), blood cancer, reprogramming, induced pluripotent stem cells (iPSCs)

Publications

Pera J, Romero-Moya D, Torralba-Sales E, Andersson R, García-Hernández V, Magallon-Mosella M, Distefano M, Berenguer Balaguer C, Castaño J, De Giorgio F, Qiu Z, Iglesias A, Spurk P, Montserrat-Vazquez S, Pasquali L, Liang Z, Català A, Florian MC, Wlodarski MW, Bigas A, Marin-Bejar O, Giorgetti A. Human iPSCs-based modeling unveils SETBP1 as a driver of chromatin rewiring in GATA2 deficiency. Nat Commun. 2025 Nov 17;16(1):10035.

Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano M, Pera J, Castaño J, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Català A, Molina O, Wlodarski MW, Bigas A, Giorgetti A. CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness. Leukemia. 2025 Sep 15.

Kotmayer L, Kozyra EJ, Kang G, Strahm B, Yoshimi A, Sahoo SS, Pastor VB, Attardi E, Voss R, Vinci L, Kaiser M, Dworzak MN, De Moerloose B, Sukova M, Starý J, Hasle H, Jahnukainen K, Polychronopoulou S, Kállay K, Smith OP, Malone A, Barzilai Birenboim S, Masetti R, Buechner J, Ussowicz M, Kjöllerström P, Bodova I, Kavcic M, Català A, Turkiewicz D, Schmugge M, de Haas V, Okhomina VI, Sotomayor C, Catalán P, Wehr C, Salzer U, Germing U, Gattermann N, Bödör C, Gray N, Lewis S, Shimamura A, Giorgetti A, Erlacher M, Niemeyer CM, Wlodarski MW. Age-dependent phenotypic and molecular evolution of pediatric MDS arising from GATA2 deficiency. Blood Cancer J. 2025 Jul 15;15(1):121.

Romero-Moya D, Pera J, Marin-Bejar O, Torralba-Sales E, Murillo-Sanjuán L, Diaz-de-Heredia C, Montoro J, Rodríguez-Ubreva J, Liquori A, Cervera J, Wlodarski MW, Català A, Giorgetti A. Multiple phenotypes and epigenetic profiles in a three-generation family history with GATA2 deficiency. Leukemia. 2025 Apr;39(4):962-966.

Marin-Bejar O, Romero-Moya D, Rodriguez-Ubreva J, Distefano M, Lessi F, Aretini P, Liquori A, Castaño J, Kozyra E, Kotmayer L, Bueno C, Cervera J, Rodriguez-Gallego JC, Nomdedeu JF, Murillo-Sanjuán L, De Heredia CD, Pérez-Martinez A, López-Cadenas F, Martínez-Laperche C, Dorado-Herrero N, Marco FM, Prósper F, Menendez P, Valcárcel D, Ballestar E, Bödör C, Bigas A, Catalá A, Wlodarski MW, Giorgetti A. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency. Haematologica. 2023 Sep 1;108(9):2551-2557.

Bigas A, Galán Palma L, Kartha GM, Giorgetti A. Using Pluripotent Stem Cells to Understand Normal and Leukemic Hematopoietic Development. Stem Cells Transl Med. 2022 Nov 18;11(11):1123-1134.

Kotmayer L, Romero-Moya D, Marin-Bejar O, Kozyra E, Català A, Bigas A, Wlodarski MW, Bödör C, Giorgetti A. GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects. Br J Haematol. 2022 Nov;199(4):482-495.

Fernández-Muñoz B, Rosell-Valle C, Ferrari D, Alba-Amador J, Montiel MÁ, Campos-Cuerva R, Lopez-Navas L, Muñoz-Escalona M, Martín-López M, Profico DC, Blanco MF, Giorgetti A, González-Muñoz E, Márquez-Rivas J, Sanchez-Pernaute R. Retrieval of germinal zone neural stem cells from the cerebrospinal fluid of premature infants with intraventricular hemorrhage. Stem Cells Transl Med. (2020). Online ahead of print.

Castaño J, Aranda S, Bueno C, Calero-Nieto FJ, Mejia-Ramirez E, Blanco E, Wang X, Prieto C, Zabaleta L, Rovira M, Jiménez-Delgado S, Gӧttgens B, Di Croce L, Menendez P, Raya A and Giorgetti A. GATA2 directly represses cardiac fates to promote hematopoietic specification of human mesoderm. Stem Cell Reports, 13:515-529. (2019).

Giorgetti A*; Castaño J; Bueno C; Diaz GR; Delgado M, Espinosa L; Menendez P*. Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro. Exp Hematol. 45; 85-93. (2017). *co-corresponding authors
Muñoz-López A, Romero-Moya D, Prieto D, Ramos-Mejía V, Agraz-Doblas A, Varella I, Buschbeck M, Palau A, Carvajal-Vergara A, Giorgetti A, Ford A, Lako M, Granada I, Ruiz-Xivillé, Rodríguez-Perales S, Stam RW, Fraga MF, Nakanishi M, Cazzaniga G, Bardini M, Fernandez AF, Bueno C, Menendez P. Developmental refractoriness of MLL-rearranged human B-cell acute leukemias to reprogramming into pluripotency. (2016). Stem Cell Reports;7:602-618. (2016).
Castaño, J; Menéndez, P; Bruzos, C; Straccia, M; Sousa, M; Zabaleta, L; Vázquez, N; Zubiarrain, A; Canals, JM; Sonntag, KC; Ugedo, L; Carvajal-Vergara, X; Torrecilla, M; Sánchez-Pernaute, R; Giorgetti, A. Rapid and efficient direct conversion of human hematopoietic cells into neurons by SOX2 and c-MYC Sendai vectors. Stem Cell Reports. 3:1118-1131. (2014).
Ruiz S, Gore A, Li Z, Panopoulos AD, Montserrat N, Fung HL, Giorgetti A, Bilic J, Batchelder EM, Zaehres H, Schöler HR, Zhang K, Izpisua Belmonte JC. Analysis of protein-coding mutations in hiPSCs and their possible role during somatic cell reprogramming. Nat Commun. 4, 1382. (2013).
Giorgetti A, Marchetto MC, Li M, Yu D, Fazzina R, Mu Y, Adamo A, Paramonov I, Castaño J, Monasterio MB, Bardy C, Cassiani-Ingoni R, Liu GH, Gage FH, Izpisúa Belmonte JC.. Cord blood-derived neuronal cells by ectopic expression of SOX2 and c-MYC. Proc Natl Acad Sci U S A. 109, 12556-61. (2012)
Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, Lee JH, Loh YH, Manos PD, Montserrat N, Panopoulos AD, Ruiz S, Wilbert ML, Yu J, Kirkness EF, Izpisúa Belmonte JC, Rossi DJ, Thomson JA, Eggan K, Daley GQ, Goldstein LS, Zhang K. Somatic coding mutations in human induced pluripotent stem cells. Nature. 471, 63-7 (2011).
Giorgetti A, Montserrat N, Rodriguez-Piza I, Azqueta C, Veiga A and Izpisúa Belmonte JC. Generation of induced pluripotent stem cells from human cord blood with only two factors: Oct4 and Sox2. Nature Protocols. 5, 811-820 (2010)
Giorgetti A, Montserrat N, Aasen T, Gonzalez F, Rodríguez-Pizà I, Vassena R, Raya A, Boué S, Barrero MJ, Aran-Corbella B, Torrabadella M, Veiga A and Izpisúa Belmonte JC.. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell. 5, 353-358. (2009)
Current Members
Current Members
Headshot of Damià Romero
Damià Romero
Research Assistant
Biosketch
Headshot of Joan Pera
Joan Pera
PhD student
Biosketch
Headshot of Maria Magallon
Maria Magallon
PhD student
Biosketch
Headshot of Eric Torralba
Eric Torralba
Bioinformatician
Biosketch
Headshot of Raimon Bundó
Raimon Bundó
PhD student
Biosketch
P-CMRC logo
P-CMRC logo
X-twitter
© P-CMRC 2009-2025– Legal Notice – Privacy Policy

Alessandra Giorgetti
Principal Investigator, Regenerative Medicine Program of IDIBELL
Associate Professor, Department of Pathology and Experimental Therapy, University of Barcelona
Associated Group Leader of P-CMRC
agiorgetti@idibell.cat

Alessandra Giorgetti holds a PhD in Molecular Medicine (2004) from the University of Milan, (Italy). She continued her Postdoc training in Dr. Rafii’s Laboratory, at Weill Cornell Medical College in New York. She then was a Research Associate (2008-2011) at the Center of Regenerative Medicine of Barcelona (CMRB). There, she consolidated her skills in stem cells and acquired invaluable knowledge in reprogramming technologies. From 2011 to 2013 she was the head of the Laboratory of Hematopoiesis and Blood Disorders at the Inbiomed Foundation, San Sebastian (Spain). In 2014 she was awarded with the prestigious Spanish grant Ramon y Cajal, in the area of Biomedicine. The same year she joined Pablo Menendez’ Lab, at the Josep Carreras Leukaemia Research Institute, as associate Investigator.

Since 2016 she is employed at the CMRB, where she established her own research group studying the molecular mechanisms that regulate human hematopoietic stem cell development, differentiation and oncogenic transformation. GATA2 deficiency disorder became a more recent focus of her group. Employing multi-OMICs methodologies (genome, transcriptome and epigenome), human induced pluripotent stem cells (hiPSCs) and in vivo experimental models she is interested to understand how GATA2 haploinsufficiency contributes to myelodysplastic syndrome /acute myeloid leukemia development in pediatric patients.

Damià Romero
Research Assistant
dromero@idibell.cat

Damià Romero holds a BS in Biology (2010), an MS in Biomedicine (2011), and a PhD in Biomedicine (2017) obtained at the University of Barcelona (UB)

During his PhD at Josep Carreras Leukemia Research Institute in Barcelona (IJC-UB) (Prof. Pablo Menendez) he developed an iPSC model to recapitulate the Coenzyme Q10 deficiency to understand the genotype-phenotype association. He used isogenic iPSCs to study differences on the metabolism and cell differentiation. He also studied the contribution of mitochondria in cord blood-derived hematopoietic stem cells. During this period, he performed a short stay of 4 month at Institute of Genetics Medicine (IGM) at the University of Newcastle in the laboratory of Prof. Majlinda Lako to better understand the biology of the iPSCs.

He spent three years as a postdoc in Dr. Jeroen Roose´s lab at University of California San Francisco (UCSF) developing a mouse model with the expression of human RasGRP1 resulting in impaired blood differentiation. This study was combined with a synthetic lethal screening to discover new targets to treat T-ALL.

During these years he has acquired expertise in cell culture techniques (including stem cells, hES, hiPSC), molecular biology, immunology, gen editing, mice model handling and deep knowledge of hematopoiesis and leukemia.

In 2020, he joined P-CMRC in Giorgetti’s Lab as Research Assistant.

Joan Pera
PhD student
jperag@idibell.cat

Joan obtained his BSc in Microbiology at the Autonomous University of Barcelona (2020). During his Bachelor Thesis he had the opportunity to be part of the Dynamical Systems Biology group led by Jordi Garcia-Ojalvo, under the supervision of Dr. Carlos Toscano-Ochoa. Here, he gained wet lab skills such as cloning, while at the same time he started learning programming with MatLab. After that, he decided to enroll himself in a MSc in Biomedical Research at Pompeu Fabra University (2021). During his Master Thesis he worked with Lentivirus and CRISPR-Cas9 system to enhance the delivery in Gene Therapy at the Translational Synthetic Biology group led by Dr. Marc Güell.

His passion for science has not stopped growing for that reason in September 2021 he joined the P-CMR(C) as a Ph.D. student at Hematopoietic Stem Cell Biology & Leukemogenesis group under the supervision of Dr. Alessandra Giorgetti.

Maria Magallon
PhD student
mmagallon@idibell.cat

Maria obtained her BSc in Biotechnology at the Institut Químic de Sarrià, Barcelona, in 2021. During her Bachelor Thesis she spent six months working on one of Dr. Robert Teixidó’s projects, entitled “Improved bactericidal effectiveness of modified silver nanoparticles: protein corona effect” in the biomaterials’ laboratory. After that, she decided to enroll herself in a MSc in Biomedical Research at Pompeu Fabra University (2022). During her Master’s Thesis she worked in the Hemotopietic Stem Cell Biology and Leukemogenesis group led by Dr. Alessandra Giorgetti, where she has the opportunity to keep working at thanks to the Ministry of Education of Andorra’s grant she obtained.

For that reason, in January 2023 she joined again the P-CMR[C] as a Ph.D. student under the supervision of Dr. Alessandra Giorgetti.

Headshot of Eric Torralba
Eric Torralba
Bioinformatician
etorralba@idibell.cat
Eric Torralba obtained his BSc in Biomedical Engineering from Universitat Politècnica de Barcelona (2022), where he was trained in various biomedical domains. His passion for processing and analyzing data began during his undergraduate studies, culminating in his BSc thesis, where he spent six months with the Neurophotonics and Mechanical Systems Biology group under the supervision of Prof. Dr. Michael Krieg, gaining insights into processing biomedical data.
Afterward, he decided to further deepen his knowledge in programming skills and biomedical data by enrolling himself in a MSc in Biomedical Data Science at Universitat Rovira i Virgili (2024). He was trained in acquiring, formalizing, cleaning, quality controlling, processing, and analyzing various types of medical data. As part of his master’s thesis, he collaborated with Arnau de Vilanova University Hospital to perform adherence and survival analysis on different Chronic Lymphocytic Leukemia oral administrated medication.
His passion and dedication to solving real-world problems led him to join the P-CMR[C] in May 2024 as a Bioinformatician for the Hematopoietic Stem Cell Biology & Leukemogenesis group under the supervision of Dr. Alessandra Giorgetti.
Headshot of Raimon Bundó
Raimon Bundó
PhD student
rbundo@idibell.cat

Raimon Bundó holds a Bachelor’s Degree in Marine Sciences and Technologies (2023) from the Polytechnic University of Catalonia and a Master’s Degree in Molecular Biotechnology (2024) from the University of Barcelona.

During 2022-2023 Raimon was at Silvia G. Acinas laboratory for an 8-months Bachelor’s degree internship at ICM-CSIC, Ecology of Marine Microbes Group. After that, he did a 10-months Master’s internship during 2023-2024 at Silvia G. Acinas laboratory at ICM-CSIC, Ecology of Marine Microbes Group. He also obtained a research technician contract for a project of the European Recovery, Transformation and Resilience Plan (PTI OCEANS+).

Currently, Raimon has started as a PhD student in the Giorgetti’s Lab, Hematopoietic Stem Cell Biology and Leukemogenesis.